Influence of Bacillus anthracis 34F₂ Sterne Antigen Preparations in Combination with Cobaltarabinogalactan on the Subpopulation Structure of B-lymphocytes (Communication 2)

Study of Bacillus anthracis 34F2 Sterne antigenic preparation S-2 and its combined use with nanostructured cobalt-arabinogalaktan (Со-АG) is presented. The ability of these preparations to stimulate proliferation and differentiation of B-lymphocytes is demonstrated. However, content of the B-lymphocyte circulating subpopulations depends on the time of observation. Co-AG exhibits adjuvant properties enhanced the immunogenic features of the S-2 B. anthracis 34F2 Sterne that may indicate its availability as an adjuvant in the construction of chemical vaccines.

сибирская язва, антигены, нанокомпозиты, иммунитет, В-лимфоциты, anthrax, antigen, blood, nanocomposite, immunity, B-lymphocytes

1. Zverev V.V., Semenov B.F., Khaitov R.M. Vaccines and vaccination: national manual. Moscow: GEOTAR-Media; 2011 (in Russian).

2. Onishchenko G.G., Kozhuhov V.V. Anthrax: actual problems of development and implementation of health protection. Moscow: Medicine; 2010 (in Russian).

3. Lukyanova S.V., Kravets E.V., Shkaruba T.T. Anthrax vaccines and potential for thein improvement. Inf. bolezni. 2011; 9 (1): 51 – 56 (in Russian).

4. Bielinska A.U., Janczak K.W., Landers J.J., Makidon P., Sower L.E., Peterson J.W. et al. Mucosal immunization with a novel nanoemulsion-based recombinant anthrax protective antigen vaccine protects against Bacillus anthracis spore challenge. Infect. Immun. 2007; 75 (8): 4020 – 4029.

5. Cybulski Jr.R.J., Sanz P., O’Brien A.D. Anthrax vaccination strategies. Molecular Aspects of Medicine. 2009; 30 (6): 490 – 502.

6. Gauthier Y.P., Tournier J.N., Paucod J.C., Corre J.P., Mock M., Goossens P.L. et al. Efficacy of vaccine based on protective antigen and killed spores against experimental inhalational anthrax. Infect. Immun. 2009; 77 (3): 1197 – 1207.

7. Xu L., Frucht D. M. Bacillus anthracis: a multi-faceted role for anthrax lethal toxin in thwarting host immune defenses. Int. J. Biochem. Cell. Biol. 2007; 39 (1): 20 – 24.

8. Mikshis N.I., Popova P.Yu., Kudryavtseva O.M., Goncharova A.Yu., Popov Yu.A., Kutyrev V.V. Immunogenicity of protective antigen extracted from asporogenic recombinant strain Bacillus anthracis. Zh. Microbiol. 2011; 1: 44 – 48 (in Russian).

9. Kulshreshtha P., Aggarwal S., Jaiswal H., Bhatnagar R. S-layer homology motif is an immunogen and confers protection to mouse model against anthrax. Mol. Immunol. 2012; 50 (1 – 2): 18 – 25.

10. Uchida M., Harada T., Enkhtuya J., Kusumoto A., Kobayashi Y., Chiba S. et al. Protective effect of Bacillus anthracis surface protein EA1 against anthrax in mice. Biochem Biophys Res Commun. 2012; 421 (2): 323 – 328.

11. Dubrovina V.I., Markov E.Yu., Konovalova Zh.A., Yuryeva O.V., Nicolaev V.B., Lukyanova S.V. et al. Influence of Bacillus anthracis 34F2 Sterne antigen preparations in combination with nanocomposites on the immune response of experimental animals. Epidemiology and Vaccinal Prevention. 2014; 3 (76): 92 – 96 (in Russian).

12. Dubrovina V.I., Vityazeva S.A., Konovalova Zh.A., Starovoitova T.P., Mukhturgin G.B., Suhov B.G. et al. Comparative characteristic of nanostructured argento-1- vinyl-1,2,4-triazol, argentogalactomannan and cobaltarabinogalactane action to immune reaction of experimental animals. Nanotekhnologii i okhrana zdoroviya. 2012; 3(12): 31 – 38 (in Russian).

13. Dubrovina V.I., Voitkova V.V., Lukyanova S.V., Yuryeva O.V., Nicolaev V.B., Aleksandrova G.P. Influence of Bacillus anthracis 34F2 Sterne antigen preparations in combination with сobaltarabinogalactan on the apoptosis blood cells in vitro. Epidemiology and Vaccinal Prevention.2014; 4 (77): 78 – 82 (in Russian).

14. Vityazeva S.A., Starovoitova T.P., Dubrovina V.I. Comparative characteristic of a macroorganism immune response at oral and parenteral injection of metalcontaining nanobiocomposite. Bulletin of the East-Siberian Centre of Science of the Siberian Branch of the Russian Academy of Med. Sciences. 2012; 2 (84): 114 – 117 (in Russian).

15. Aleksandrova G.P., Medvedeva S.A., Grishchenko L.A., Suhov B.G., Trofimov B.A. A method of preparation of nanodimensional metal and metalloxide particles. Patent of the Russian Federation № 2260500; 2005 (in Russian).

16. Rodriguez-Alba J.C., Moreno-Garcia M.E., Sandoval-Montes C., Rosales-Garcia V.H., Santos-Argumedo L. CD38 induces differentiation of immature transitional 2 B lymphocytes in the spleen. Blood. 2008; 111 (7): 3644 – 3652.

17. Sims G.P., Ettinger R., Shirota Y., Yarboro C.H., Illei G.G., Lipsky P.E. Identification and characterization of circulating human transitional B cells. Blood. 2005; 105 (11): 4390 – 4398.

18. Sandoval-Montes C., Santos-Argumedo L. CD38 is expressed selectively during the activation of a subset of mature T cells with reduced proliferation but improved potential to produce cytokines. J. Leukoc. Biol. 2005; 77: 513 – 521.

19. Hiepe F., Dorner T., Hauser A.E., Hoyer B.F., Mei H., Radbruch A. Long-lived autoreactive plasma cells drive persistent autoimmune inflammation. Nat mune disease. Nat Rev Rheumatol. 2009; 5: 433 – 441.

20. Yoshida T., Mei H., Dorner T., Hiepe F., Radbruch A., Fillatreau S. et al. Memory B and memory plasma cells. Immunol. Rev. 2010; 237: 117 – 139

21. Querec T.D., Akondy R.S., Lee E.K., Cao W., Nakaya H.I., Teuwen D. et al. Systems biology approach predicts immunogenicity of the yellow fever vaccine in humans. Nat. Immunol. 2009; 10: 116 – 125.

22. He X. S., Sasaki S., Narvaez C. F., Zhang C., Liu H., Woo J.C. et al. Plamablast-derived polyclonal antibody response after influenza vaccination. J. Immunol. Methods. 2011; 365: 67 – 75.